

Drug and Therapeutics Committee – Minutes – Approved

Date / Time	8 th January 2015
Venue	The Committee Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs Wendy Hornsby, Senior Pharmacy Technician.
Quorate: Yes / No	Yes

Attendance	Mr S Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services Mr P O'Brien, Deputy Chief Pharmacist Mrs C Grantham, Medicines Management Nurse Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Dr O Ogunbambi, Consultant Rheumatologist Mrs K Beal, Lay Trust Member Dr L Witvliet, GP Prescribing Lead, Hull CCG Prof M Lind, Vice Chair, Professor of Oncology Dr E Williamson, Consultant Microbiologist Dr H Klonin, Consultant Paediatrician Mr K McCorry, Local Pharmaceutical Advisor, ERCSU
-------------------	---

Apologies	Mrs J Lyon, Head of Medicines Management, North Yorks and Humber CSU Dr A Harley, GP Prescribing Lead, ERY CCG Mr P Renwick, Vascular Surgeon
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2015.01.01	Apologies	As above.					
2015.01.02	Declarations of Interest	AM informed the committee he had attended a meeting in Newcastle, where dinner was provided, regarding riociguat.	Noted	No further action			
2015.01.03	Minutes of the previous meeting	The minutes were accepted as a true record.	Accepted				
2015.01.04	Action Tracker	<p>NICE Guidance HK has highlighted CG183 to colleagues. The department is waiting until a new allergy lead is in place before any changes to local practice are made.</p> <p>Ophthalmic Specials Formulary has been updated by WH.</p> <p>New Product Requests ML has written to applicants and WH has updated the formulary.</p> <p>New Product Requests – Xeomin DC has contacted Wendy Cayton and arranged a meeting with service managers to discuss reviewing botulinum use.</p> <p>New Product Requests DC has spoken to Stephen Miller regarding</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>	<p></p> <p></p> <p></p> <p></p> <p>New Action: DC to</p>	<p></p> <p></p> <p></p> <p></p> <p>DC</p>	<p></p> <p></p> <p></p> <p></p> <p>02/15</p>	<p>01/15</p> <p>01/15</p> <p>01/15</p> <p>01/15</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		costings of allergy products.		ask MM to check with JLy about funding position			
		New Product Requests Octenidine Nasal Gel and Ganciclovir Eye Gel have been added to formulary.	Action complete				01/15
		New Product Requests CG has started preparing a PGD for use of Naseptin cream.	Action complete				01/15
		NICE Guidance ML has written to Peter Sedman Re orilistat & CG189.	Action complete				01/15
		NICE Guidance SG has discussed nalmefene with MM. MM discussed with HFT. Nalmefene will be initiated by specialist services at HFT, so available via a SCF. Patients admitted to HEY for non-alcohol related treatment could continue, however treatment is likely be withheld/reviewed if patients are admitted with acute alcohol-related conditions.	To be added to formulary for continuation of treatment, not for initiation by HEY	Add to formulary	WH	02/15	
		NICE Guidance ML has highlighted TA 323 to service team.	Action complete				01/15
		MHRA DSU ML has written to Dr Abouda and Dr Adams re boceprevir/telaprevir.	Action complete				01/15
		Correspondence Received SG has written bullet points in response to CSU TAG and forwarded to ML. Points to be	Action complete				01/15
				New Action: ML to	ML	02/15	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>raised with CSU.</p> <p>AOB WH has circulated meeting times and dates for 2015.</p> <p>AOB Royal College guidelines for poisoning are still to be added to formulary.</p>	<p>Action complete</p> <p>WH to add to formulary</p>	<p>write to CSU</p> <p>WH to add to formulary</p>	<p>WH</p>	<p>03/15</p>	<p>01/15</p>
2015.01.05	New Product Requests	Riociguat – Dr S Faruqi.	Approved for use. NHSE commissioning position was awaited, so until funding confirmed – would be available via NHSE IFR only	AM to write to applicant WH to update formulary	AM/WH	02/15	
2015.01.06	NICE Guidance	<p>December 2014</p> <ul style="list-style-type: none"> CG192 Antenatal and Postnatal Mental Health. CG131 Colorectal Cancer. Oxaliplatin has been in use for many years, but was not listed on the formulary document (in error). CG37 Postnatal Care. CG190 Intrapartum care: care of health women and their babies during childbirth. 	<p>Noted - applies to HFT</p> <p>Noted - oxaliplatin to be added to formulary</p> <p>Noted</p> <p>Noted</p>	<p>No further action</p> <p>WH to add to formulary</p> <p>No further action</p> <p>No further action</p>	<p>WH</p>	<p>02/15</p>	<p>01/15</p> <p>01/15</p> <p>01/15</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> CG191 Pneumonia – this guideline raised a discussion around the Trust empiric antibiotic guideline and the antibiotic guidelines to reduce the risk of <i>C. difficile</i>, followed by DME, where co-trimoxazole was suggested. TA327 Dabigatran for treatment & secondary prevention of DVT and/or PE. TA328 Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal). 	<p>SG to raise NICE CG191 at next ACAT meeting</p> <p>Noted, already on formulary for stroke/cardiology/orthopaedics</p> <p>Noted – not on formulary</p>	<p>SG to feedback after next ACAT meeting</p> <p>WH to amend formulary to state “In line with NICE guidance”, as with other NOACs</p> <p>No further action</p>	<p>SG</p> <p>WH</p>	<p>03/15</p> <p>02/15</p>	<p>01/15</p>
2015.01.07	MHRA Drug Safety update	December 2014 Hyrdoxyethyl starch products (HES) – have returned to the UK market following regulatory review. There are new contra-indications, warnings and monitoring. Voluven HES is listed on the HEY formulary.	SG to discuss at Surgery HG governance meeting.	SG to raise at Surgery HG governance meeting	SG	03/15	
2015.01.08	Correspondence Received	Contrast Media Tender for Radiology – MultiHance injection & Dotarem syringes/bottles for injection. POB informed the committee that radiology was assessing different products for ease of use and compatibility of use before agreeing a new tender. The committee asked for reassurance that the products were currently on formulary and that there were no safety concerns.	POB to check raised safety issues and feed back to committee	POB to feedback	POB	03/15	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>Pregabalin (Lyrica) NICE CG173 has been redrafted to recommend use of licensed branded product for neuropathic pain. If generic pregabalin is used this may infringe patent if used off licence.</p> <p>Evicel Fibrin Sealant Mr Loubani has written to the committee to inform them that Evicel Fibrin Sealant has been used by three different consultants on five different patients, as agreed. The product was found to be very easy to use, with a short preparation time and clinically effective.</p> <p>D&T Finance Representative Alison Drury (previously on maternity leave) has written to the committee to inform them that she will be available should the committee have any finance queries but would not routinely be attending any further meetings.</p>	<p>The committee agreed to await national/NICE guidance before making any decisions.</p> <p>Add to formulary for cardiothoracic surgery only.</p> <p>The committee agreed this was a reasonable position.</p>	<p>No further action</p> <p>WH to update formulary</p> <p>No further action</p>	<p>WH</p>	<p>02/15</p>	<p>01/15</p> <p>01/15</p>
2015.01.11	Chairs Approvals	<p>Eculizumab – Haemolytic Uremic Syndrome (HUS) – Dr M Chanayireh SG informed the committee that he had discussed with Dr Chanayireh after patient had received third dose and had been informed that the patient was making a good recovery. However, there are issues around the funding, as the course costs approx. £45k and has been declined by both the CCG and NHSE IFR processes.</p>	<p>DC has asked for a report to be written regarding this chairs approval to forward to Alan Webb and Alison Drury. Paper to be discussed at next D&T</p>	<p>DC to feed back regarding the report</p>	<p>DC</p>	<p>02/15</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2015.01.13	Issues to escalate to Clinical Quality Committee	None.					
2015.01.14	Any other Business	JLy has emailed to ask that the use of bevacizumab over ranibizumab be discussed. It was agreed that this would be discussed at the meeting to be held between HEY and CCG leads regarding ophthalmology products later in the month.	Noted	No further action			01/15
2015.01.15	Date and Time of Next Meeting	Thursday 12 th February 2015, 8.15am – 9.30am. Committee Room, Alderson House, HRI					